COCH Envoy Medical, Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1840877 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.1%
TTM net income YoY4.3%
TTM EPS YoY164.4%
Revenue 3-yr CAGR-1.4%
Net income 3-yr CAGR—
Margins
Gross margin-352.8%
Operating margin-10,151.5%
Net margin-9,026.4%
FCF margin—
EBITDA margin-10,020.8%
Returns
ROE—
ROA-152.5%
ROIC (approx.)—
Asset turnover0.02x
Leverage & solvency
Liabilities / assets106.0%
Debt / equity—
Current ratio1.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio10.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $241,000 | $225,000 |
| Cost of revenue | $874,000 | $742,000 |
| Gross profit | -$633,000 | -$517,000 |
| R&D expense | $12.49M | $10.18M |
| SG&A expense | $7.93M | $6.83M |
| Operating income | -$22.27M | -$19.26M |
| Interest expense | $1.59M | $816,000 |
| Pretax income | -$23.76M | -$20.80M |
| Net income | -$23.76M | -$20.80M |
| EBITDA | -$21.97M | -$19.08M |
| EPS (basic) | -1.23 | -1.49 |
| EPS (diluted) | -1.23 | -1.49 |
| Weighted avg. shares (diluted) | 23.26M | 18.79M |
| Balance sheet | ||
| Cash & equivalents | $3.74M | $5.48M |
| Receivables | $34,000 | $38,000 |
| Inventory | $1.55M | $1.71M |
| Current assets | $6.28M | $8.90M |
| PP&E, net | $1.03M | $1.27M |
| Total assets | $8.56M | $11.54M |
| Current liabilities | $11.56M | $7.54M |
| Total liabilities | $20.32M | $30.38M |
| Shareholders' equity | -$12.16M | -$18.84M |
| Shares outstanding | — | 21.33M |
| Cash flow statement | ||
| Operating cash flow | -$18.20M | -$17.95M |
| Capital expenditure | $179,000 | $980,000 |
| Free cash flow | -$18.38M | -$18.93M |
| Investing cash flow | -$179,000 | -$980,000 |
| Financing cash flow | $16.63M | $20.20M |
| Depreciation & amortization | $302,000 | $173,000 |
| Stock-based compensation | $657,000 | $562,000 |
| Dividends paid | $1.82M | $2.45M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.